GE MEDICAL SYSTEMS

The Orthopedic Oncology Market is projected to grow from USD 1.2 billion in 2023 to USD 2.3 billion by 2033, driven by rising bone cancer cases, advanced treatment modalities, and early diagnosis awareness. Innovations in surgical techniques and imaging technologies are improving patient outcomes, while precision medicine and minimally invasive options are boosting market growth.

At the October 3 Nashville Institute for Value-Based Medicine event, Travis Osterman presented on leveraging AI for precision immunotherapy, focusing on predicting patient responses and toxicities. His project, a collaboration between Vanderbilt University Medical Center and GE Healthcare, aims to use existing patient data for widespread implementation. The project's outcomes, published in the Journal of Clinical Oncology, showed potential to improve clinical trial efficiency and patient outcomes by identifying optimal candidates for treatments and reducing toxicity risks.

The Artificial Intelligence In Precision Medicine Market is projected to experience significant growth by 2032, driven by increasing demand, technological advancements, and expanding customer base. Key players include Intel AI, IBM, GE Healthcare, and Thermo Fisher Scientific. The market is segmented by product type (hardware, software, services) and application (oncology, neurosciences, immunology, respiratory). The report provides comprehensive analysis, including market size, trends, drivers, and competitive landscape.

GE HealthCare manufactures Omni Legend PET/CT scanner in Waukesha, Wisconsin, marking its first U.S. production. The 100th U.S. install is scheduled at UW Health Eastpark Medical Center in Madison. Launched in 2022, the system features improved sensitivity, efficiency, and AI-powered assistance for patient care.

MedGenome appoints Felix Olale as President and CEO, and Jennifer Rose as EVP and CCO to lead U.S. operations, aiming to accelerate growth and innovation in precision medicine and multiomics solutions.

Global Microarray Market to reach US$ 11.5 Billion by 2033, driven by advanced molecular diagnostic tools, cancer research, and AI integration in data analysis.

Biomarkers indicate biological processes, pathogenic processes, or responses to interventions. Categories of Alzheimer's Disease (AD) biomarkers include susceptibility/risk, diagnostic, monitoring, prognostic, predictive, response/pharmacodynamic, and safety biomarkers. The Division of Neuroscience (DN) at NIA is committed to advancing biomarker research for AD/ADRD, emphasizing open science practices and data sharing. NIA outlines research milestones to validate biomarkers and provides funding opportunities and resources for AD/ADRD biomarker development. FDA-approved products for AD/ADRD include in vitro diagnostic tests and PET tracers. CLEAR-AD, funded by NIA, aims to identify next-generation AD biomarkers and establish a precision medicine approach for multi-omics biomarker discovery and validation.

Nucleus RadioPharma announces new 53,000-square-foot manufacturing facility in Mesa, AZ, set to open in mid-2026, addressing the shortage of high-quality development and manufacturing space for theranostic products. The facility will create 50 new skilled jobs and enhance patient access to life-saving treatments, expediting clinical trials by up to 30%.

Global Personalized Medicines Market to grow from USD 588.31 Million in 2023 to USD 1,007.05 Million by 2031, driven by advancements in genetic technology and rising prevalence of rare diseases. North America leads in demand due to high healthcare expenditure, while Asia-Pacific shows the fastest growth. Market segments include diagnostics, genetic testing, and end-uses like hospitals and diagnostic centers. Key players are investing in R&D and collaborations, and insurance coverage and healthcare budgets are expanding.

The article discusses the importance of enabling JavaScript for optimal app performance.